Method for determination severity level of trophological insufficiency in patients with chronic obstructive pulmonary disease |
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
IPC classes for russian patent Method for determination severity level of trophological insufficiency in patients with chronic obstructive pulmonary disease (RU 2390026):
Method of forecasting retrocessions of larynx cancer / 2389030
In patients suffering from larynx cancer after surgical oncotomy in the course of dispensary observation levels of androsteron and estradiol in 24-hour collection urine are examined and their ratio to each other are determined. At ratio level more than 3 emergence of disease retrocession or metastasis in the near future is forecasted. At ratio level lower than 3 a long-lasting recurrence-free period is forecasted.
 Diagnostic technique for desynchronosis of hypophysial thyroid system in patients with severe bronchial asthma, previously not taking glucocorticoid therapy / 2382366
Diagnostic technique for desynchronosis of hypophysial thyroid system in the patients with severe bronchial asthma refers to medicine. Substance consists that blood of the patients is radioimmunoassayed for concentration of TSH, T3, T4 hormones. The obtained data are processed to draw a graphic curve of circadian rhythm for each hormone that provides a basis to determine individual acrophase and batiphase time. The acrophase (confidence interval) TSH development biorhythm 9 h 11 min (confidential interval 4 h 57 min to 13 h 26 min), T3 hormone - 15 h 01 min (confidential interval 8 h 05 min to 21 h 57 min) T4 hormone - 16 h 34 min (confidential interval 8 h 55 min to 24 h 13 min), and batiphase of circadian TSH secretion rhythm 21 h to 22 h, T3 - 2 h to 4 h, T4 4 h to 5 h ensure to diagnose apparent desynchronosis of hypophysial thyroid system.
Method for predicting depressive behaviour in aged primate, rates of aging and development of stress-dependent pathological changes / 2377570
Invention refers to medicine and veterinary science and can be used for predicting depressive behaviour of an aged primate, rates of ageing and development of stress-dependent pathological changes. According to the claimed invention, an aged primate is examined for psychoemotional reaction on soft and acute psychoemotional stress effect, molar concentration ratio of cortisol and dehydroepiandrosterone sulphate in peripheral blood plasma and percentage concentration of cortisol in peripheral blood plasma in the evening (20 o'clock 45 minutes - 21 o'clock 15 minutes) to concentration of cortisol in peripheral blood plasma in the morning (8 o'clock 45 minutes - 9 o'clock 15 minutes) to predict depressive behaviour in the aged primate with accelerated rates of ageing and development of stress-dependent pathological changes in depressive reaction on soft and acute psychoemotional stress effect, if molar concentration ratio of cortisol and dehydroepiandrosterone sulphate in peripheral blood plasma is not less than 4.3, and concentration of cortisol in peripheral blood plasma in the evening to concentration of cortisol in peripheral blood plasma in the morning is not less than 66%.
Method of estimating efficiency of neoadjuvant autohemochemotherapy in patients suffering from carcinoma of cervival stump / 2375063
Invention concerns medicine, namely oncology and can be used in estimation of clinical effectiveness factors in treatment of carcinoma of cervical stump. Daily urine is analysed for estradiol content and if decreased after treatment from initial level within 8.44-12.85 nmol/days, positive antineoplastic effect of treatment is stated, and if urine estradiol content is maintained in the treated patients within 8.81-11.38 nmol/days, the absence of antineoplastic effect is stated. The obtained results allow considering dynamics of estradiol content in daily urine of the patients suffering from carcinoma of cervical stump prior to AHCT as an additional laboratory test to estimate efficiency of presented pharmacotherapy. Observed positive clinical effect is confirmed by higher operability and improved life quality of the patients.
Method of determining effeciency of larynx cancer treatment / 2375003
Invention relates to medicine, namely to oncology and can be applied in presence of locally advanced process. In daily urine of patients before treatment tetrahydro-11-desoxycortisol is determined. If its level before treatment does not exceed 2 mcmol/day relapse-free period is forecasted during 2 and more years; initial level of fraction over 2 mcmol/day indicates about disease relapse or metastases during first year after treatment.
Way of forecasting of restoration of menstrual function at patients with nervous anorexia / 2363002
Invention concerns medicine, namely to gynecology, and can be used at treatment of patients with amenorrhea caused by nervous anorexia. Level of leptin is defined in blood serum using enzyme immunoassay method for realisation of the way of forecasting of restoration of menstrual function at patients with a nervous anorexia. Then an index of mass of a body (BMI) and a parity leptin/BMI is counted. In case the parity leptin/BMI makes 0.8 and more - normalisation of menstrual function is prognosticated.
Way of diagnostics of male sterility / 2362167
Invention concerns medicine area, namely to andrology, and concerns diagnostics of male sterility. The way includes studying compaction degree of chromatin of spermatozoids, percentage of defective cells in an ejaculate, level of B in blood serum. On the basis of the received data diagnostic index DI is calculated; its value helps to diagnose sterility, or absence of pathology.
 Method of diagnosing functional hyperprolactinaemia in girls / 2351935
In girls with suspected functional hyperprolactinaemia determined are level of prolactin two hours after falling asleep, concentration of general triiodtrionin, cortisol, and ultra-sound examination of small pelvis organs is carried out in order to determine volume of right ovary. On the basis of obtained data canonical value (K) is calculated by formula, and if K is greater than (-2.28) and lower than 1.27 functional hyperprolactinaemia is determined.
 Method of diagnosing hormonally inactive microadenomas of hypophysis in girls / 2351934
Invention can be used for diagnosing hormonally inactive microadenomas of hypophysis (IAH) in girls. In order to realise the method levels of prolactin in blood is determined in girls with suspected two hours after falling asleep and at 6 o'clock in the morning. On the basis of obtained data, canonical value (K) is calculated by formula, and if K is greater than (-1.69) and smaller than 1.86 IAH is diagnosed.
Method of determination of orientation of pathological process at cancer of ovaries / 2350966
Invention concerns medicine, namely to onco-gynecology. The essence of the method consists in the following: level of Testosteron is defined and at its content peer or above 2.5 nmol/l, intraoperative in blood of women with tumorous formations of ovaries before operation. In a tissue of a tumour of ovaries the maintenance of Testosteron is defined and at augmentation of its indicator above 2 nmol/g operation of full volume is carried out.
Method for differential diagnostics of mammary diseases in men / 2244308
The present innovation deals with biochemical trials: before the onset of therapy in men one should detect blood content of thyroid hormone - free thyroxine - and at its level being 10.3-12.9 pmol/l one should diagnose mammary cancer, at the level of free throxine being 18.7-31.0 pmol/l - one should predict gynecomastia. The method enables to detect the direction of pathological process and carry out due correction of therapy tactics in men with either gynecomastia or mammary cancer.
Method for predicting the delay of intrauterine fetal development / 2246733
The method deals with studying blood serum of pregnant woman to detect the content of insulin-like growth factor (IGF) and vascular-endothelial growth factor (VEGF) and calculate the coefficient of their ratio: at its value being equal to 28.5 and lower it is possible to diagnose the delay of fetal development.
Method for differential diagnostic of chronic hepatitis and hepatic cirrhosis / 2254577
Thyroglobulin content is determined in blood serum using enzyme immunoassay. When thyroglobulin level is increased by 2 times and more compared in contrast with normal one chronic hepatitis is diagnosed, and when thyroglobulin level is decreased by 1.5-2.5 times in contrast with normal one hepatic cirrhosis is diagnosed.
Method for evaluating combined schizophrenia treatment based on atypical antipsychotic drugs and rations and electroconvulsive shock therapy / 2256181
Method involves determining dehydroepiandrosterone sulfate concentration in blood serum. Its growth above 30% when compared to the initial one being observed, treatment efficiency is determined as negative.
Method for diagnosing obliterated forms of congenital suprarenal gland cortex hyperplasia / 2261447
Method involves applying high effectiveness liquid chromatography for determining cortisol, cortisone 11-deoxycorticosterone, 11-deoxycortisone concentration in blood and free cortisol and free cortisone excretion with urine. Ratios of F/E and FF/FE are calculated, where F is the cortisol level in blood; E is the cortisone level in blood; FF is the free cortisol excretion with urine and FE is the free cortisone excretion with urine. The cortisol level in blood not exceeding norm and at least two of three signs: F/E ratio reduction by 25% and more, FF/FE ratio reduction by 25% and more, free cortisol excretion with urine being equal to 25% and more, obliterated forms of congenital suprarenal gland cortex hyperplasia is diagnosed. Corticosterone level in blood growing by 50% and higher, 21-hydroxylase defect is considered to be the case. 11-deoxycorticosterone and/or 11-deoxycortisone concentration in blood being et or greater than 50%, 11β-hydroxylase defect is considered to be the case.
 Method for diagnosing atrophic gastritis cases / 2262706
Method involves making pepsinogen 1, gastrin and Helicopter pylori infection marker combinations analysis and making input of the obtained results into data processing means comprising operation system, means for receiving, transmitting and processing data. The mentioned data processing means is usable for comparing the measured concentration value of a substance under study to a threshold value associated to the substance under study and producing information as a response to comparison results and additionally to other entered data. A set and software are used for implementing the method.
Method for predicting relapse of mammary cancer / 2263319
In the course of surveying in menopausal women after complex therapy one should state the development of mammary cancer at decreased ratio of estriol concentration to the sum of estrone and estradiol urinary concentrations from 1.68±0.23 in relapse-free patients up to 0.74±0.12 - in patients living without relapses for less than a year, up to 0.65±0.13 in patients living without relapse from 2 up to 6 years and up to 0.50±0.10 in patients with relapse-free period from 6 to 10 years. The innovation provides pre-clinical detection of mammary cancer relapse.
Method for predicting fetoplacental insufficiency in pregnant women with thyroid diseases / 2263919
Except detecting placental lactogen in blood serum one should study the content of alphafetoprotein. At placental lactogen content being below 75% against the norm and content of alphafetoprotein below 70% against the norm it is possible to conclude upon availability of fetoplacental insufficiency.
Method for predicting cholecystitis and cholelithiasis / 2263920
While diagnosing cholecystitis and cholelithiasis due to ultrasound testing one should additionally study blood plasma and bile to detect there the content of prostaglandins PGE2 and PGF2α. At PGE2/PGF2α ratio in blood plasma being equal to 6 and more, and, also, at decreased level of biliary cholecystokinin-pancreosimin by 38% and more, biliary PGE2 by 59% and more and increased level of biliary prostaglandin PGF2α by 5.9 times and more against the norm one should diagnose chlecystitis and cholelithiasis. The innovation enables to detect the above-mentioned diseases at earlier stage.
Method for predicting powerless labor in pregnant nodular goiter surgically treated on goiter occasion during pregnancy under medical supervision / 2273456
Method involves determining thyroid gland node diameter and thyrotropic hormone by applying ultrasonic examination approach. Histological examination is carried out with conclusion concerning morphologic nature being obtained like nodular colloid proliferating goiter or thyroid gland adenoma. Diagnostic index Σ is calculated from formula Σ=0.49*K1+0.07*K2-0.5*K3+1.76*K4-1.53, where K1 is the thyroid gland node diameter; K2 is the TTH concentration; K3 is the nodular colloid proliferating goiter index equal to 1 or 0; K4 is the thyroid gland adenoma index equal to 1 or 0. Diagnostic index Σ being less than zero, conclusions concerning powerless labor threat is to be drawn.
|
FIELD: medicine. SUBSTANCE: body weight index (BWI) is evaluated; if it is lower than 20 kg/m2, additional analysis is needed to determine the serum leptin concentration. If it is within 16.01±0.64 to 10.15±0.91 ng/ml, the absence of trophological insufficiency is diagnosed, while the values within 5.49±0.46 to 2.26 ng/ml enable to diagnose trophological insufficiency of medium severity, while the values 1.90 to 0.72±0.09 ng/ml indicate severe trophological insufficiency. EFFECT: higher accuracy of clinical assessment of severity of trophological insufficiency in the patients with chronic obstructive pulmonary disease. 4 ex, 1 tbl
The invention relates to medicine: pulmonology, primary care, particularly to a method of evaluating the severity trophological failure in patients with chronic obstructive pulmonary disease (COPD). COPD is characterized by a number extrapulmonary manifestations that define critical system component of the disease. Systemic effects modify the course of the disease, aggravate its prognosis [1, 2]. Trophological failure (TN), manifested by weight loss, depletion of muscle mass, adipose tissue, holds a leading position in several systemic manifestations, due to the fact that brings not only a clear contribution to the development of the disease, but is associated with high risk of mortality [3, 4]. Given the role of trophological status in the prognosis of COPD, relatively recently, new methods of assessing the severity of patients. .R.Celli et al. (2004) [5] developed the BODE index, combining respiratory and systemic manifestations of COPD, including group estimated parameters of the severity of the disease, the body mass index (BMI). The deficit of body weight may be due to any component of the structure of body weight, leading of which are fat and protein. Therefore, more accurate metrics, which can determine the degree of deficiency of the component patterns of body weight, pradalago severity trophological failure, that will more accurately determine the amount of therapy to correct it. Closest to the present invention is a method of assessment trophological failure by determining the body mass index (BMI), which is calculated as the ratio of body weight (MT in kg) by height (in meters)squared: BMI=MT/Growth2(kg/m2). The interpretation of BMI is conducted according to the classification criteria for this indicator Kaplan-Meier [8]. Normal BMI is defined in the range from 20 to 24 kg/m2. About trophological failure is judged by the reduction in BMI below 20 kg/m2with increasing values of BMI greater than 24 kg/m2diagnose overweight, a BMI of more than 29 kg/m2means the development of obesity [8]. The known method is not sufficiently informative to clinical positions in relation to the assessment of the severity trophological failure, because there is no clearly established criteria, characterizing the development of this condition. The known method is also informative to establish the nature of the deficiency of the structural components of body mass, in particular the depletion of adipose tissue in patients with COPD, it has the disadvantage of a limited scope. A new technical challenge - improving the accuracy of clinical information and the extension is blasti used to estimate the severity trophological failure in patients with chronic obstructive pulmonary disease. To solve the problem in the method of assessment of the severity trophological failure in COPD patients, consisting in the determination of body mass index (BMI), when its value is below 20 kg/m2additionally carry out the determination of serum concentrations of leptin and its values from 16,01±0,64 to 10.15±0,91 ng/ml diagnose the absence trophological failure, when it is from 8,44±0.70-4,13±0.45 ng/ml diagnose mild trophological failure, when it is from 5,49±0,46 to 2.26±0,35 ng/ml diagnose medium trophological failure, when it is from 1,90 to 0.72±0.09 ng/ml diagnose severe trophological failure. The method is as follows. A patient with a diagnosis of chronic obstructive pulmonary disease (COPD), having a BMI below 20 kg/m2to determine the severity trophological failure and the nature of its manifestation in the program standard survey additionally include determining serum concentrations of leptin (ng/ml) and when the value of serum leptin is 16,01±0,64-to 10.15±0,91 ng/ml, diagnose the absence trophological failure when the value of serum leptin is 8,44±0,70-up 4,13±0.45 ng/ml, diagnose mild triolo the systematic failure when the value of serum leptin, equal 5,49±0,46 to 2.26±0,35 ng/ml, diagnosed medium trophological failure when the value of leptin serum below 1,90 to 0.72±0.09 ng/ml diagnose severe trophological failure. If thus revealed the severity trophological failure, the doctor will be able to apply the appropriate method of correction of deficient conditions in order to maintain a stable metabolic homeostasis. Example 1 Sick'ev A.S., 46 years old, was discharged from the pulmonology Department of the city hospital №3 with a diagnosis of Chronic obstructive pulmonary disease stage I, phase of clinical remission. From history revealed that he was in for 10 years. On a routine visit to her primary care physician, except the hard breathing over the lung fields on auscultation of the lungs, other pathology it is not revealed. At physical examination visual signs trophological failure is not detected. BMI equal to 21 kg/m2that confirmed the absence of trophological failure in the patient. In the pulmonary Department before discharge, the patient was examined the level of leptin in the blood serum. His figure was consistent with the norm 16,01 ng/ml. the Doctor on the basis of research results, Ovidius is camping in the absence trophological failure, gave recommendations for treatment, which consists in the fact that the treatment program includes only group of drugs aimed at maintaining remission phase of the disease without medical correction trophological status. Patient recommended further observation in the mode of examination and control of BMI 1 time in a year, when you drop below 20 kg/m2recommended study of the level of leptin serum to assess the severity of the development trophological failure and then carrying out the corresponding medical treatment. Example 2 Patient Yusupov A.I. (54 years) is observed continuously from a physician-pulmonologist diagnosed with COPD stage II. At regular checkups physician during the physical examination, the patient noted the depletion of subcutaneous fat, which indirectly indicates the possibility of development trophological failure, and this may adversely affect the course and prognosis of disease. The doctor made a calculation of BMI, which was below 20 kg/m2(19.8 kg/m2), and to decide on the severity trophological failure, the survey included a study of leptin serum enzyme-linked immunosorbent assay (ELISA). The results showed that the patient level l is ptin equal 8.44 ng/ml, what characterized mild trophological failure due to depletion of adipose tissue. Thus, in a patient with COPD has objective data, diagnose not only the degree of development trophological failure, but data about the lack of a specific component of the body structure, which allows the doctor to purposefully choose the tactics of therapy. Based on the results of the research, recommendations were made for treatment of the patient, namely, that in the treatment of COPD includes a group of drugs aimed at maintaining remission phase COPD and correction established severity trophological failure. The patient had been assigned multicomponent enzyme preparations in a dose of 1 tablet/capsule 3 times a day, improves digestion and absorption of fat in 2 months. The results of the control study showed that BMI was restored to 20.8 kg/m2, leptin serum recovered to 12,72 ng/ml Thus, in a patient with COPD stage II was restored to a normal state trophological status. Recommended further observation mode of the clinical examination. Example 3 Patient Mikhailov FI 53 years old was admitted to the examination in the pulmonary Department of the city hospital №3 with a diagnosis of Chronic the Skye obstructive lung disease stage II, stable current. From history revealed that sick for 24 years. At the time of receipt, except complaints and clinical data characterizing the severity of COPD, were filed complaints about General weakness, decreased performance, fatigue. At physical examination the patient had noticed the condition of low power supply, depletion of subcutaneous fat basis. In the standard plan of survey, in addition to clinical, laboratory studies confirming the stage of COPD were included study according to the proposed method, which consists in determining BMI to decide on the severity trophological failure, which in the survey included the study of leptin serum by ELISA. The study results confirmed the patient's stage of COPD. BMI was equal to 19.6 kg/m2according to the results of the study serum leptin was equal 5,49 ng/ml, which was characterized by the average degree trophological failure due to depletion of adipose tissue. Thus, in a patient with COPD is defined objective data, diagnose the severity development trophological failure. Based on the results of the research, recommendations were made for treatment of the patient, namely, that in the program Le is placed COPD were included in the group of drugs, aimed at maintaining remission phase of COPD, and the correction of identified trophological failure grade. The patient had been assigned multicomponent enzyme preparations in a dose of 2 tablets/capsules 3 times a day, improves digestion and absorption of fats. Therapy enzyme preparations were carried out within 3 months. The results of the control study showed that BMI was restored to 20 kg/m2, leptin serum recovered to 12.78 ng/ml Thus, in a patient with COPD stage II was restored to a normal state trophological status. Recommended further observation mode of the clinical examination. Example 4 Patient Kravchenko G.S. 58 years went on preventive care in the pulmonary Department of the city hospital №1 with a diagnosis of Chronic obstructive pulmonary disease stage III, stable current. From history revealed that he was in for 26 years. Upon receipt, except complaints and clinical data characterizing the stage of the course of COPD, were filed complaints about General weakness, decreased performance, fatigue. At physical examination the patient had noticed the condition of low power supply, depletion of subcutaneous fat basis. In the standard plan of survey, in addition to clinical, laboratory and the research, confirming the stage of COPD were included study according to the proposed method, which consists in determining BMI and study leptin serum by ELISA. The study results confirmed the patient's stage of COPD. BMI was equal to 19.2 kg/m2according to the results of the analysis of blood serum indicator of leptin was equal to 0.72 ng/ml, which was characterized by the presence of severe trophological failure due to depletion of adipose tissue. Thus, in a patient with COPD is defined objective data, diagnose severe severity development trophological failure. Based on the results of the research, recommendations were made for treatment of the patient, namely, that in the treatment of COPD includes a group of drugs aimed at maintaining the remission phase of COPD, and the correction of identified trophological failure severe. Underreporting of clinical data characterizing the severity trophological deficiency may worsen the prognosis of the disease. Given the low rate of leptin serum physician has ordered the patient prolonged therapy multicomponent enzyme medications that patient should take after inpatient treatment with subsequent control of the m values of leptin serum. The results of a study conducted over 6 months, showed that the BMI of the patient increased to 19.8 kg/m2indicator leptin serum rose to 5,42 ng/ml Thus, clinical observation showed that the patient trophological failure severe severity transferred to medium severity, improved General condition of the patient in terms of exercise tolerance. The patient is recommended to always take maintenance therapy multicomponent enzyme preparations and 1 times a year to monitor the leptin serum. Proposed criteria selected on the basis of the interpretation of the results of clinical observations. The total number of body adipose tissue and its total energy reserve reflects leptin - the hormone of fat cells (adipocytes) [6, 7]. Low leptin levels reflect a shortage of pool of fat cells and insufficient energy reserves of adipose tissue that characterizes the presence of not only T, but also low-energy reserve of body adipose tissue. Underestimation of these data in the clinical condition of the patient will contribute to the progression of the disease. Determination of serum concentrations of leptin (ng/ml) was carried out using enzyme-linked immunosorbent assay test system (DSL) is produced in the production of the U.S. according to the attached instruction set. Record the results of tests carried out on a spectrophotometer at a wavelength of 450 nm on an ELISA analyzer "Multiskan (Finland) with the subsequent construction of calibration curves using special computer programs. First, we set the standard indicators of the concentration of leptin in the blood serum of healthy people and control group (n-15), having a BMI of 20 to 24 kg/m2(table 1). Serum concentrations of leptin in the control group was characterized by a sample average 15,54±0,78 ng/ml. The diagnosis of COPD and randomization of patients in groups depending on the stage of the disease, we followed the guidelines of the program GOLD 2006 (a decline of forced expiratory volume in 1-Yu second - FEV1) [9]. Clinically the patients were in a stable phase of the disease. The study included patients with stage IV COPD very severe, patients with pulmonary decompensation of the heart (the right ventricle was assessed by Doppler ultrasonography)were excluded patients who had a condition affecting the levels of serum concentration of leptin: receiving corticosteroids, cancer, connective tissue disease, Smoking, symptoms of acute infectious inflammation. In patients with stage I/group (n-2) BMI was within the normal range, the sample mean value of the concentration of leptin serum (16,01±0.64 ng/ml) had no statistically significant differences from control group (P>0,05). The underweight of varying severity were determined in patients with II-III stages of the disease (table 1). In the group of patients with COPD II-III stages, not having defecit body mass (n-32), the sample mean values of serum concentrations of leptin were equal 12,78±0,87 ng/ml and 10,15±0,91 ng/ml, respectively. In COPD patients II-III stages (n-20)having a body weight deficit from 10%to 20%, the sample mean values of serum concentrations of leptin were equal 8,44±0,70 ng/ml and 4.13±0.45 ng/ml, respectively. Serum concentrations of leptin in patients with COPD II-III stages, with a deficit of body weight below 20% to 30% (n-14), was equal 5,49±0,ng/ml and 2.26±0,35 ng/ml, respectively. Serum concentrations of leptin in patients with COPD stage III, with a deficit of body weight more than 30% (n-5), was equal to 0.72±0.09 ng/ml Thus, on the basis of the conducted research we have established criteria for serum concentrations of leptin, which characterizes the degree of deficiency of body adipose tissue and mean severity trophological failure COPD patients. Statistical processing of the results of the studies were conducted using standard packages of applied programs. The results, not only the us in the form M±M, where M is the arithmetic mean, m is the average error of the arithmetic. The critical significance level (p) for the testing of statistical hypotheses in our research were taken ≤0,05. Thus, the proposed method of assessment of the severity trophological failure COPD patients by determining the serum concentration of leptin allows you to more accurately assess the severity of depletion of body adipose tissue as one of the leading components of body weight. The evaluation of the severity trophological failure in COPD patients on the value of the serum concentrations of leptin allow you to define more adequate volume therapy for the correction trophological failure, depending on the degree of its manifestation, and include it in the standard treatment of patients with COPD with the aim of decreasing the intensity of this negative risk factor and improve the quality of life of patients.
Literature 1. Agusti A.G.N., Noguera a, Sauleda J. et al. Systemic effects of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21(2):347-360. 2. Agusti A.G. Systemic effects of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2005; 2:367-370. 3. Gray-Donald K, Gibbons, L., Shapiro, S.H. et al. Nutritional status and mortality in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1996; 153:961-966. 4. Landbo C, Prescott e, Lange p, et al. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160:1856-1861. 5. Celli BR, Cote C.C., J.M. Marin et al. The body-mass, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 10:1005-1012. 6. Auwerx J. and Staels B. Leptin. Lancet 1998; 351:737-742. 7. Flier J. S. Leptin expression and action: new experimental paradiagns. Proc. Natl. Acad. Sci. USA. 1997 94:4242-4245. 8. Kaplan e, Meier P. Nonparametric estimation from incomplete observation. J. Am. Stat. Assoc. 1958; 53:457-481. 9. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for diagnosis, management, and prevention ofchronic obstructive pulmonary desease. NHLBI / WHO workshop report. Last updated 2006. www.goldcopd.org /. The method of assessment of the severity trophological failure in patients with chronic obstructive pulmonary disease (COPD), which consists in determining body mass index (BMI), characterized in that when the value is less than 20 kg/m2additionally carry out the determination of serum concentrations of leptin and its value from (16,01±0,64) to (10,15±0,91) ng/ml diagnose the absence trophological failure, when its value from (5,49±0,46) to 2.26 ng/ml diagnose medium trophological failure, when it is from 1,90 to (0,72±0,09) ng/ml diagnose severe trophological failure.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||